News Detail

This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Benzinga · 09/22 12:20

Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Piper Sandler analyst Paul Newsome upgraded Metlife Inc (NYSE:MET) from Neutral to Overweight and raised the price target from $99 to $110. MetLife closed at $96.64 on Monday. See how other analysts view this stock.
Northcoast Research analyst Jim Sanderson upgraded Brinker International Inc (NYSE:EAT) from Neutral to Buy and announced a $275 price target. Brinker International shares closed at $200.30 on Friday. See how other analysts view this stock.
Keybanc analyst Steve Barger upgraded Plexus Corp (NASDAQ:PLXS) from Sector Weight to Overweight and announced a $300 price target. Plexus closed at $252.36 on Monday. See how other analysts view this stock.
Morgan Stanley analyst Kallum Titchmarsh upgraded West Pharmaceutical Services Inc (NYSE:WST) from Equal-Weight to Overweight and boosted the price target from $365 to $400. West Pharmaceutical shares closed at $361.78 on Monday. See how other analysts view this stock.
Cantor Fitzgerald analyst Olivia Brayer Saunders upgraded Omeros Corp (NASDAQ:OMER) from Neutral to Overweight and announced a $22 price target. Omeros closed at $18.49 on Monday. See how other analysts view this stock.

Considering buying PLXS stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.